APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral and Injectable Medications for Type 2 Diabetes

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026

23 December 2025133 pages

Choose your research edition.

Industry ResearchOral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral and Injectable Medications for Type 2 Diabetes market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral and Injectable Medications for Type 2 Diabetes is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral and Injectable Medications for Type 2 Diabetes is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral and Injectable Medications for Type 2 Diabetes include United Laboratories, Yiling Pharmaceutical, Takeda, Tonghua Dongbao, Sanofi, Novo Nordisk, Merck, Eli Lilly and Jiangsu Wanbang, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral and Injectable Medications for Type 2 Diabetes market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral and Injectable Medications for Type 2 Diabetes Market by Company

United Laboratories

Yiling Pharmaceutical

Takeda

Tonghua Dongbao

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Wanbang

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

Ganli Pharmaceutical

Beijing Beilu Pharmaceutical

bayer

AstraZeneca

Boehringer Ingelheim

Biocon

Oral and Injectable Medications for Type 2 Diabetes Segment by Type

Insulin

Biguanides

Sulfonylureas

SGLT2 Inhibitors

GLP‑1 Receptor Agonists

DPP‑4 Inhibitors

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Application

Clinic

Hospital

Pharmacy

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral and Injectable Medications for Type 2 Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral and Injectable Medications for Type 2 Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral and Injectable Medications for Type 2 Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral and Injectable Medications for Type 2 Diabetes manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral and Injectable Medications for Type 2 Diabetes by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral and Injectable Medications for Type 2 Diabetes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral and Injectable Medications for Type 2 Diabetes Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral and Injectable Medications for Type 2 Diabetes Sales (k units) of Manufacturers (2021-2026) Table 7. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral and Injectable Medications for Type 2 Diabetes Revenue of Manufacturers (2021-2026) Table 9. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral and Injectable Medications for Type 2 Diabetes Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Oral and Injectable Medications for Type 2 Diabetes Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Product Type & Application Table 14. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral and Injectable Medications for Type 2 Diabetes by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. United Laboratories Company Information Table 19. United Laboratories Business Overview Table 20. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 22. United Laboratories Recent Developments Table 23. Yiling Pharmaceutical Company Information Table 24. Yiling Pharmaceutical Business Overview Table 25. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 27. Yiling Pharmaceutical Recent Developments Table 28. Takeda Company Information Table 29. Takeda Business Overview Table 30. Takeda Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 32. Takeda Recent Developments Table 33. Tonghua Dongbao Company Information Table 34. Tonghua Dongbao Business Overview Table 35. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 37. Tonghua Dongbao Recent Developments Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 42. Sanofi Recent Developments Table 43. Novo Nordisk Company Information Table 44. Novo Nordisk Business Overview Table 45. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 47. Novo Nordisk Recent Developments Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 52. Merck Recent Developments Table 53. Eli Lilly Company Information Table 54. Eli Lilly Business Overview Table 55. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 57. Eli Lilly Recent Developments Table 58. Jiangsu Wanbang Company Information Table 59. Jiangsu Wanbang Business Overview Table 60. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 62. Jiangsu Wanbang Recent Developments Table 63. Jiangsu Hengrui Pharmaceuticals Company Information Table 64. Jiangsu Hengrui Pharmaceuticals Business Overview Table 65. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 67. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 72. Pfizer Recent Developments Table 73. Beijing Double-Crane Pharmaceutical Company Information Table 74. Beijing Double-Crane Pharmaceutical Business Overview Table 75. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 77. Beijing Double-Crane Pharmaceutical Recent Developments Table 78. Huadong Medicine Company Information Table 79. Huadong Medicine Business Overview Table 80. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 82. Huadong Medicine Recent Developments Table 83. Ganli Pharmaceutical Company Information Table 84. Ganli Pharmaceutical Business Overview Table 85. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 87. Ganli Pharmaceutical Recent Developments Table 88. Beijing Beilu Pharmaceutical Company Information Table 89. Beijing Beilu Pharmaceutical Business Overview Table 90. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 92. Beijing Beilu Pharmaceutical Recent Developments Table 93. bayer Company Information Table 94. bayer Business Overview Table 95. bayer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 97. bayer Recent Developments Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 102. AstraZeneca Recent Developments Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 107. Boehringer Ingelheim Recent Developments Table 108. Biocon Company Information Table 109. Biocon Business Overview Table 110. Biocon Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 112. Biocon Recent Developments Table 113. Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (k units) Table 115. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2026) Table 116. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032) & (k units) Table 117. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2027-2032) Table 118. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2026) Table 120. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2027-2032) Table 122. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 124. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 125. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 129. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 130. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 134. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 135. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 139. South America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 140. South America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 144. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 145. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 148. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 149. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2026) Table 150. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2027-2032) Table 151. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2026) Table 154. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2027-2032) Table 155. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2026) & (USD/unit) Table 156. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2027-2032) & (USD/unit) Table 157. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 158. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 159. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2026) Table 160. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2027-2032) Table 161. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2026) Table 164. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2027-2032) Table 165. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2026) & (USD/unit) Table 166. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2027-2032) & (USD/unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Oral and Injectable Medications for Type 2 Diabetes Distributors List Table 170. Oral and Injectable Medications for Type 2 Diabetes Customers List Table 171. Oral and Injectable Medications for Type 2 Diabetes Industry Trends Table 172. Oral and Injectable Medications for Type 2 Diabetes Industry Drivers Table 173. Oral and Injectable Medications for Type 2 Diabetes Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral and Injectable Medications for Type 2 Diabetes Product Image Figure 5. Global Oral and Injectable Medications for Type 2 Diabetes Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral and Injectable Medications for Type 2 Diabetes Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032) & (k units) Figure 8. Global Oral and Injectable Medications for Type 2 Diabetes Average Price (USD/unit) & (2021-2032) Figure 9. Insulin Product Image Figure 10. Biguanides Product Image Figure 11. Sulfonylureas Product Image Figure 12. SGLT2 Inhibitors Product Image Figure 13. GLP‑1 Receptor Agonists Product Image Figure 14. DPP‑4 Inhibitors Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. Pharmacy Product Image Figure 19. Others Product Image Figure 20. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Manufacturers in 2025 Figure 21. Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Manufacturing Sites & Headquarters Figure 22. Global Top 5 and 10 Oral and Injectable Medications for Type 2 Diabetes Players Market Share by Revenue in 2025 Figure 23. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 25. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region in 2025 Figure 26. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region in 2025 Figure 27. North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country in 2025 Figure 28. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 29. North America Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Country (2021-2032) Figure 30. United States Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Canada Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Mexico Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country in 2025 Figure 34. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 35. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Country (2021-2032) Figure 36. Germany Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. France Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. U.K. Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Italy Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Russia Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Spain Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Netherlands Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Switzerland Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Sweden Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Poland Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country in 2025 Figure 47. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 48. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Country (2021-2032) Figure 49. China Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Japan Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South Korea Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. India Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Australia Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Taiwan Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. South America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country in 2025 Figure 58. South America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 59. South America Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Country (2021-2032) Figure 60. Brazil Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Argentina Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Chile Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country in 2025 Figure 64. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Country (2021-2032) Figure 66. Egypt Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Oral and Injectable Medications for Type 2 Diabetes Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2032) Figure 72. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2032) Figure 73. Global Oral and Injectable Medications for Type 2 Diabetes Price (USD/unit) by Type (2021-2032) Figure 74. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2032) Figure 75. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2032) Figure 76. Global Oral and Injectable Medications for Type 2 Diabetes Price (USD/unit) by Application (2021-2032) Figure 77. Oral and Injectable Medications for Type 2 Diabetes Value Chain Figure 78. Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges

Scope & coverage.

Types
  • Insulin
  • Biguanides
  • Sulfonylureas
  • SGLT2 Inhibitors
  • GLP‑1 Receptor Agonists
  • DPP‑4 Inhibitors
  • Others
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • United Laboratories
  • Yiling Pharmaceutical
  • Takeda
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Wanbang
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • Ganli Pharmaceutical
  • Beijing Beilu Pharmaceutical
  • bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size (2021-2032)
  4. 2.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032)
  5. 2.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Market Average Price (2021-2032)
  6. 2.3 Oral and Injectable Medications for Type 2 Diabetes by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Insulin
  9. 2.3.3 Biguanides
  10. 2.3.4 Sulfonylureas
  11. 2.3.5 SGLT2 Inhibitors
  12. 2.3.6 GLP‑1 Receptor Agonists
  13. 2.3.7 DPP‑4 Inhibitors
  14. 2.3.8 Others
  15. 2.4 Oral and Injectable Medications for Type 2 Diabetes by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 Pharmacy
  20. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral and Injectable Medications for Type 2 Diabetes Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral and Injectable Medications for Type 2 Diabetes Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Product Type & Application
  8. 3.8 Global Manufacturers of Oral and Injectable Medications for Type 2 Diabetes, Established Date
  9. 3.9 Global Oral and Injectable Medications for Type 2 Diabetes Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 United Laboratories
  2. 4.1.1 United Laboratories Company Information
  3. 4.1.2 United Laboratories Business Overview
  4. 4.1.3 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  6. 4.1.5 United Laboratories Recent Developments
  7. 4.2 Yiling Pharmaceutical
  8. 4.2.1 Yiling Pharmaceutical Company Information
  9. 4.2.2 Yiling Pharmaceutical Business Overview
  10. 4.2.3 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  12. 4.2.5 Yiling Pharmaceutical Recent Developments
  13. 4.3 Takeda
  14. 4.3.1 Takeda Company Information
  15. 4.3.2 Takeda Business Overview
  16. 4.3.3 Takeda Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  18. 4.3.5 Takeda Recent Developments
  19. 4.4 Tonghua Dongbao
  20. 4.4.1 Tonghua Dongbao Company Information
  21. 4.4.2 Tonghua Dongbao Business Overview
  22. 4.4.3 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  24. 4.4.5 Tonghua Dongbao Recent Developments
  25. 4.5 Sanofi
  26. 4.5.1 Sanofi Company Information
  27. 4.5.2 Sanofi Business Overview
  28. 4.5.3 Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  30. 4.5.5 Sanofi Recent Developments
  31. 4.6 Novo Nordisk
  32. 4.6.1 Novo Nordisk Company Information
  33. 4.6.2 Novo Nordisk Business Overview
  34. 4.6.3 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  36. 4.6.5 Novo Nordisk Recent Developments
  37. 4.7 Merck
  38. 4.7.1 Merck Company Information
  39. 4.7.2 Merck Business Overview
  40. 4.7.3 Merck Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  42. 4.7.5 Merck Recent Developments
  43. 4.8 Eli Lilly
  44. 4.8.1 Eli Lilly Company Information
  45. 4.8.2 Eli Lilly Business Overview
  46. 4.8.3 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  48. 4.8.5 Eli Lilly Recent Developments
  49. 4.9 Jiangsu Wanbang
  50. 4.9.1 Jiangsu Wanbang Company Information
  51. 4.9.2 Jiangsu Wanbang Business Overview
  52. 4.9.3 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  54. 4.9.5 Jiangsu Wanbang Recent Developments
  55. 4.10 Jiangsu Hengrui Pharmaceuticals
  56. 4.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 4.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 4.10.3 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  60. 4.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 4.11 Pfizer
  62. 4.11.1 Pfizer Company Information
  63. 4.11.2 Pfizer Business Overview
  64. 4.11.3 Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  66. 4.11.5 Pfizer Recent Developments
  67. 4.12 Beijing Double-Crane Pharmaceutical
  68. 4.12.1 Beijing Double-Crane Pharmaceutical Company Information
  69. 4.12.2 Beijing Double-Crane Pharmaceutical Business Overview
  70. 4.12.3 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  72. 4.12.5 Beijing Double-Crane Pharmaceutical Recent Developments
  73. 4.13 Huadong Medicine
  74. 4.13.1 Huadong Medicine Company Information
  75. 4.13.2 Huadong Medicine Business Overview
  76. 4.13.3 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  78. 4.13.5 Huadong Medicine Recent Developments
  79. 4.14 Ganli Pharmaceutical
  80. 4.14.1 Ganli Pharmaceutical Company Information
  81. 4.14.2 Ganli Pharmaceutical Business Overview
  82. 4.14.3 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  84. 4.14.5 Ganli Pharmaceutical Recent Developments
  85. 4.15 Beijing Beilu Pharmaceutical
  86. 4.15.1 Beijing Beilu Pharmaceutical Company Information
  87. 4.15.2 Beijing Beilu Pharmaceutical Business Overview
  88. 4.15.3 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  90. 4.15.5 Beijing Beilu Pharmaceutical Recent Developments
  91. 4.16 bayer
  92. 4.16.1 bayer Company Information
  93. 4.16.2 bayer Business Overview
  94. 4.16.3 bayer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  96. 4.16.5 bayer Recent Developments
  97. 4.17 AstraZeneca
  98. 4.17.1 AstraZeneca Company Information
  99. 4.17.2 AstraZeneca Business Overview
  100. 4.17.3 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  102. 4.17.5 AstraZeneca Recent Developments
  103. 4.18 Boehringer Ingelheim
  104. 4.18.1 Boehringer Ingelheim Company Information
  105. 4.18.2 Boehringer Ingelheim Business Overview
  106. 4.18.3 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  108. 4.18.5 Boehringer Ingelheim Recent Developments
  109. 4.19 Biocon
  110. 4.19.1 Biocon Company Information
  111. 4.19.2 Biocon Business Overview
  112. 4.19.3 Biocon Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  114. 4.19.5 Biocon Recent Developments
5 Global Oral and Injectable Medications for Type 2 Diabetes Market Scenario by Region
  1. 5.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021-2032
  3. 5.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021-2026
  4. 5.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2027-2032
  5. 5.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region: 2027-2032
  8. 5.4 North America Oral and Injectable Medications for Type 2 Diabetes Market Facts & Figures by Country
  9. 5.4.1 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  11. 5.4.3 North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oral and Injectable Medications for Type 2 Diabetes Market Facts & Figures by Country
  16. 5.5.1 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  18. 5.5.3 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oral and Injectable Medications for Type 2 Diabetes Market Facts & Figures by Country
  41. 5.7.1 South America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  43. 5.7.3 South America Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  2. 6.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  2. 7.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral and Injectable Medications for Type 2 Diabetes Value Chain Analysis
  2. 8.1.1 Oral and Injectable Medications for Type 2 Diabetes Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process
  5. 8.2 Oral and Injectable Medications for Type 2 Diabetes Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral and Injectable Medications for Type 2 Diabetes Distributors
  8. 8.2.3 Oral and Injectable Medications for Type 2 Diabetes Customers
9 Global Oral and Injectable Medications for Type 2 Diabetes Analyzing Market Dynamics
  1. 9.1 Oral and Injectable Medications for Type 2 Diabetes Industry Trends
  2. 9.2 Oral and Injectable Medications for Type 2 Diabetes Industry Drivers
  3. 9.3 Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges
  4. 9.4 Oral and Injectable Medications for Type 2 Diabetes Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst